- Trading by management and close relations of management
- Q1 update: Novonesis delivers 4% organic sales growth in line with expectations and reports progress on the integration
- Trading statement Q1 2024
- Resolutions from the annual shareholders’ meeting 2024
- Invitation to the annual shareholders’ meeting
- Share-based legacy RSU program granted
- 2024 outlook and pro forma financials
- Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21
- Resolutions from the Extraordinary Shareholders’ Meeting 2024
- Invitation to an extraordinary shareholders’ meeting of Novozymes A/S
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 431.10 |
---|---|
High | 438.00 |
Low | 430.70 |
Bid | 435.40 |
Offer | 435.40 |
Previous close | 432.30 |
Average volume | 675.21k |
---|---|
Shares outstanding | 414.56m |
Free float | 302.99m |
P/E (TTM) | 38.56 |
Market cap | 173.91bn DKK |
EPS (TTM) | 10.88 DKK |
Annual div (ADY) | 6.20 DKK |
---|---|
Annual div yield (ADY) | 1.42% |
Div ex-date | May 01 2024 |
Div pay-date | May 03 2024 |
Data delayed at least 15 minutes, as of May 17 2024 16:10 BST.
More ▼